United States · Platforms & data · MarketBeat
Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results
Detailed summary
Kardigan (NASDAQ:KARD) said its phase 2 trial of investigational drug ataciguat in aortic stenosis is fully enrolled and that it will assess the study’s primary endpoint at 48 weeks, rather than 24 weeks. Top-line results are expected in the second half of 2027. The KATALYST-AV trial’s primary endp
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)
